Oculis Holding AG (OCS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Oculis Holding AG (OCS) closed at USD 7.17 on 2026-10-14, a change of -65.9 % over the past year, with a market capitalization of USD 455.75M.

Oculis Holding AG recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Oculis Holding AG key figures

Previous close

USD 7.17 (2026-10-14)

1-year change

-65.9 %

Market cap

USD 455.75M

Enterprise value

USD 231.04M

P/E ratio (trailing)

-4.25

P/E ratio (forward)

-3.82

EPS (trailing)

-1.74

EPS (forward)

-1.94

PEG ratio

n/a

Price to book

1.75

Revenue growth

18.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.21

Employees

60

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Oculis Holding AG and compare it with other stocks.